PMID- 31965416
OWN - NLM
STAT- MEDLINE
DCOM- 20200724
LR  - 20200724
IS  - 1437-7772 (Electronic)
IS  - 1341-9625 (Linking)
VI  - 25
IP  - 5
DP  - 2020 May
TI  - Safety of radiotherapy for hemodialysis patients with cancer.
PG  - 978-983
LID - 10.1007/s10147-020-01621-0 [doi]
AB  - BACKGROUND: The number of hemodialysis (HD) patients is increasing worldwide, and 
      they are at a higher risk of cancer than the general population. Because HD 
      patients are more likely to have inflammation, radiotherapy (RT)-induced adverse 
      effects (AEs) are theoretically expected to be worse for HD patients. Since only 
      a few reports have been published on this subject, we aimed to evaluate the 
      tolerability of RT in HD patients. METHODS: We retrospectively analyzed AEs 
      related to RT for HD patients. Our study included patients from three 
      institutions treated between January 2007 and July 2017. The patient eligibility 
      criteria were (i) receipt of maintenance HD 2-3 times per week for end-stage 
      renal disease prior to the start of RT and (ii) pathologically confirmed 
      malignancies. The endpoints were acute and late non-hematologic AEs. RESULTS: The 
      study included 56 patients. The most common histology was head and neck cancer 
      (23%), followed by lung cancer (14%) and prostate cancer (11%). The median 
      radiation dose was 60 (range, 12-93.8) Gy at an equivalent dose in 2-Gy fractions 
      (EQD2). The RT completion rate was 96%. Patients had a median follow-up period 
      after RT of 9.1 (range 0.5-98.1) months. Grade 3 or worse acute and late AEs were 
      noted in 6 (11%) and 3 (7%) patients, respectively. In the acute phase, 2 
      patients had grade 5 AEs, both of which were infections. CONCLUSION: Our results 
      suggest that RT for HD patients is clinically tolerable. However, some patients 
      can experience severe infections related to treatment.
FAU - Hirota, Hiroshi
AU  - Hirota H
AD  - Department of Radiation Oncology, Tokyo Medical and Dental University, 1-5-45 
      Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.
AD  - Department of Radiology, Tokyo Metropolitan Ohtsuka Hospital, 2-8-1, 
      Minamiohtsuka, Toshima-ku, Tokyo, 170-8476, Japan.
FAU - Ito, Kei
AU  - Ito K
AUID- ORCID: 0000-0001-5792-3795
AD  - Division of Radiation Oncology, Department of Radiology, Tokyo Metropolitan 
      Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, 
      Bunkyo-ku, Tokyo, 113-8677, Japan. keiito@cick.jp.
FAU - Kageyama, Shun-Ichiro
AU  - Kageyama SI
AD  - Division of Radiation Oncology, National Cancer Center Hospital East, 6-5-1 
      Kashiwanoha, Kashiwa-shi, Chiba, 277-8577, Japan.
FAU - Tamamoto, Fumihiko
AU  - Tamamoto F
AD  - Department of Radiology, Tokyo Metropolitan Ohtsuka Hospital, 2-8-1, 
      Minamiohtsuka, Toshima-ku, Tokyo, 170-8476, Japan.
FAU - Karasawa, Katsuyuki
AU  - Karasawa K
AD  - Division of Radiation Oncology, Department of Radiology, Tokyo Metropolitan 
      Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, 
      Bunkyo-ku, Tokyo, 113-8677, Japan.
FAU - Yoshimura, Ryouichi
AU  - Yoshimura R
AD  - Department of Radiation Oncology, Tokyo Medical and Dental University, 1-5-45 
      Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200121
PL  - Japan
TA  - Int J Clin Oncol
JT  - International journal of clinical oncology
JID - 9616295
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Head and Neck Neoplasms/mortality/physiopathology/*radiotherapy
MH  - Humans
MH  - Kidney Failure, Chronic/therapy
MH  - Lung Neoplasms/mortality/physiopathology/*radiotherapy
MH  - Male
MH  - Middle Aged
MH  - Prostatic Neoplasms/mortality/physiopathology/*radiotherapy
MH  - Radiation Injuries/*etiology
MH  - Radiotherapy Dosage
MH  - *Renal Dialysis
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Adverse effects
OT  - End-stage renal disease
OT  - Hemodialysis
OT  - Radiotherapy
OT  - Toxicities
EDAT- 2020/01/23 06:00
MHDA- 2020/07/25 06:00
CRDT- 2020/01/23 06:00
PHST- 2019/06/18 00:00 [received]
PHST- 2020/01/07 00:00 [accepted]
PHST- 2020/01/23 06:00 [pubmed]
PHST- 2020/07/25 06:00 [medline]
PHST- 2020/01/23 06:00 [entrez]
AID - 10.1007/s10147-020-01621-0 [pii]
AID - 10.1007/s10147-020-01621-0 [doi]
PST - ppublish
SO  - Int J Clin Oncol. 2020 May;25(5):978-983. doi: 10.1007/s10147-020-01621-0. Epub 
      2020 Jan 21.